期刊
FRONTIERS IN ENDOCRINOLOGY
卷 12, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fendo.2021.624686
关键词
non-surgical therapy; Temozolomide; CAPTEM; PRRT (Peptide Receptor Radionuclide Therapy); aggressive pituitary tumors; pituitary carcinomas
资金
- Graduate School, University of Minnesota [UMF0011528]
- University of Alberta
- University Hospital Foundation
- US National Institutes of Health [AR064195]
Up to 35% of aggressive pituitary tumors recur and current treatment options often fail to inhibit tumor growth. Chemotherapeutic drugs and peptide receptor radionuclide therapy are being increasingly researched for their potential anti-tumor effects on aggressive pituitary tumors.
Up to 35% of aggressive pituitary tumors recur and significantly affect mortality and quality of life. Management can be challenging and often requires multimodal treatment. Current treatment options, including surgery, conventional medical therapies such as dopamine agonists, somatostatin receptor agonists and radiotherapy, often fail to inhibit pituitary tumor growth. Recently, anti-tumor effects of chemotherapeutic drugs such as Temozolomide, Capecitabine, and Everolimus, as well as peptide receptor radionuclide therapy on aggressive pituitary tumors have been increasingly investigated and yield mixed, although sometimes promising, outcomes. The purpose of this review is to provide thorough information on non-surgical medical therapies and their efficacies and used protocols for aggressive pituitary adenomas from pre-clinical level to clinical use.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据